LEXX Lexaria Bioscience Corp.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1348362 · Fiscal year ends 08/31
Financial factors as of 2026-05-31 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-68.5%
TTM net income YoY32.1%
TTM EPS YoY50.0%
Revenue 3-yr CAGR-14.2%
Net income 3-yr CAGR—
Margins
Gross margin100.0%
Operating margin-3,973.2%
Net margin-3,985.6%
FCF margin-3,848.6%
EBITDA margin-3,960.4%
Returns
ROE-150.3%
ROA-134.2%
ROIC (approx.)-553.9%
Asset turnover0.03x
Leverage & solvency
Liabilities / assets9.1%
Debt / equity0.00x
Current ratio10.60x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.96x
Accruals ratio-5.3%
Payout ratio—
Capex / revenue21.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-08-31 | FY20242024-08-31 |
|---|---|---|
| Income statement | ||
| Revenue | $705,923 | $464,278 |
| Cost of revenue | $2,720 | $4,822 |
| Gross profit | $703,203 | $459,456 |
| R&D expense | $8.24M | $2.36M |
| SG&A expense | $4.35M | $3.85M |
| Operating income | -$11.88M | -$5.75M |
| Interest expense | — | $7,760 |
| Pretax income | -$11.91M | -$5.81M |
| Net income | -$11.90M | -$5.80M |
| EBITDA | -$11.83M | -$5.71M |
| EPS (diluted) | -0.66 | -0.47 |
| Weighted avg. shares (diluted) | 18.00M | 12.38M |
| Banking | ||
| Net interest income | — | $14,311 |
| Balance sheet | ||
| Cash & equivalents | $1.80M | $6.50M |
| Short-term investments | $143,267 | $55,807 |
| Receivables | $368,358 | $154,477 |
| Current assets | $3.47M | $7.90M |
| PP&E, net | $228,129 | $254,709 |
| Intangibles | $307,818 | $516,676 |
| Total assets | $4.18M | $8.87M |
| Current liabilities | $1.49M | $1.10M |
| Total liabilities | $1.57M | $1.21M |
| Shareholders' equity | $2.99M | $8.04M |
| Shares outstanding | 19.56M | 19.56M |
| Cash flow statement | ||
| Operating cash flow | -$10.45M | -$4.96M |
| Capital expenditure | $24,646 | $43,014 |
| Free cash flow | -$10.48M | -$5.00M |
| Investing cash flow | -$243,019 | -$188,605 |
| Financing cash flow | $6.05M | $10.32M |
| Depreciation & amortization | $51,225 | $42,448 |
| Stock-based compensation | $859,494 | $492,236 |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.